| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis
|
Gendelman, Omer
|
|
|
19 |
7 |
p.
|
artikel
|
| 2 |
Convalescent plasma in Covid-19: Possible mechanisms of action
|
Rojas, Manuel
|
|
|
19 |
7 |
p.
|
artikel
|
| 3 |
COVID-19 gone bad: A new character in the spectrum of the hyperferritinemic syndrome?
|
Colafrancesco, Serena
|
|
|
19 |
7 |
p.
|
artikel
|
| 4 |
Cytokine storm syndrome in severe COVID-19
|
Ruscitti, Piero
|
|
|
19 |
7 |
p.
|
artikel
|
| 5 |
Editorial Board
|
|
|
|
19 |
7 |
p.
|
artikel
|
| 6 |
Fatal COVID-19 infections: Is NK cell dysfunction a link with autoimmune HLH?
|
Osman, Mohammed S.
|
|
|
19 |
7 |
p.
|
artikel
|
| 7 |
How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion
|
Sarzi-Puttini, Piercarlo
|
|
|
19 |
7 |
p.
|
artikel
|
| 8 |
Hydroxychloroquine reduces IL-6 and pro-thrombotic status
|
Sciascia, Savino
|
|
|
19 |
7 |
p.
|
artikel
|
| 9 |
Imatinib might constitute a treatment option for lung involvement in COVID-19
|
Bernal-Bello, David
|
|
|
19 |
7 |
p.
|
artikel
|
| 10 |
Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review
|
Alijotas-Reig, Jaume
|
|
|
19 |
7 |
p.
|
artikel
|
| 11 |
Interleukin-17A (IL-17A), a key molecule of innate and adaptive immunity, and its potential involvement in COVID-19-related thrombotic and vascular mechanisms
|
Raucci, Federica
|
|
|
19 |
7 |
p.
|
artikel
|
| 12 |
Molecular mimicry between SARS-CoV-2 and respiratory pacemaker neurons
|
Lucchese, Guglielmo
|
|
|
19 |
7 |
p.
|
artikel
|
| 13 |
Novel COronaVirus Disease 2019 (COVID-19) epidemic: What are the risks for systemic sclerosis patients?
|
Del Papa, Nicoletta
|
|
|
19 |
7 |
p.
|
artikel
|
| 14 |
Re: Patiently waiting for the results of anti-IL 6 therapy in severe COVID-19 infection
|
McGonagle, Dennis
|
|
|
19 |
7 |
p.
|
artikel
|
| 15 |
SARS-CoV-2 infection among patients with systemic autoimmune diseases
|
Emmi, Giacomo
|
|
|
19 |
7 |
p.
|
artikel
|
| 16 |
SARS-CoV-2 infection complicated by inflammatory syndrome. Could high-dose human immunoglobulin for intravenous use (IVIG) be beneficial?
|
Prete, Marcella
|
|
|
19 |
7 |
p.
|
artikel
|
| 17 |
Seven recommendations to rescue the patients and reduce the mortality from COVID-19 infection: An immunological point of view
|
Kronbichler, Andreas
|
|
|
19 |
7 |
p.
|
artikel
|
| 18 |
Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions
|
Jamilloux, Yvan
|
|
|
19 |
7 |
p.
|
artikel
|
| 19 |
The correlation between SARS-CoV-2 infection and rheumatic disease
|
Gao, Zhao-wei
|
|
|
19 |
7 |
p.
|
artikel
|
| 20 |
Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia?
|
Antinori, Spinello
|
|
|
19 |
7 |
p.
|
artikel
|
| 21 |
Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy
|
Toniati, Paola
|
|
|
19 |
7 |
p.
|
artikel
|
| 22 |
Transcriptional landscape of SARS-CoV-2 infection dismantles pathogenic pathways activated by the virus, proposes unique sex-specific differences and predicts tailored therapeutic strategies
|
Fagone, Paolo
|
|
|
19 |
7 |
p.
|
artikel
|
| 23 |
Why judiciously timed anti-IL 6 therapy may be of benefit in severe COVID-19 infection
|
Cunningham, Louise
|
|
|
19 |
7 |
p.
|
artikel
|
Tijdschrift beschrijving